IGC today
$0.18-$0.01 (-3.31%)close Nov 13, 2026Trend
DailyDowntrend (confirmed)
4 hourStrong Bearish
1 hourStrong Bearish
15 minStrong Bearish
5 minStrong Bearish
Daily trend turns up above $0.34
Key levels
Resistance$0.27
Resistance$0.23
Support$0.08
Latest news & SEC filings
LegalIGC Pharma wins Canada patent covering IGC-AD1 for Alzheimer's-related agitation
LegalIGC Pharma receives Canadian patent for IGC-AD1 Alzheimer's agitation therapy
All IGC news →About IGC Pharma
IGC Pharma is a clinical-stage pharmaceutical company developing therapies for Alzheimer's disease. Its lead drug candidate, IGC-AD1, is in Phase 2 trials for agitation in Alzheimer's patients, with earlier-stage programs targeting amyloid plaques, tau protein, and metabolic disorders. The company also uses artificial intelligence to build models for early detection of Alzheimer's and to optimize clinical trials. It operates in the United States and Colombia.
Based on the company's 10-K filed Jun 27, 2025.
NYSE · Healthcare
IGC Pharma, Inc. (IGC)
What Is the Price Target for IGC?
SEPT Low Target
$0.00
SEPT Mid Target
$0.00
SEPT High Target
$0.00
Analyst Consensus
$0.00
Is IGC a Buy or Sell Right Now?
Thesis
- •Revenue growing -5.5% YoY with STRONG trend — consistent growth.
- •SEC filings signal active product innovation — 2 new product/expansion keywords detected in 10-K. R&D investment stable.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for IGC.
Start Free Trial →Is IGC Overvalued or Undervalued?
Valuation Verdict
N/A
Methods Used
N/A
Fair Value
$N/A
35
Moat Score
NONE
3/9
Piotroski Score
-18.2
Altman Z-Score
What Is Smart Money Doing with IGC?
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Mukunda Ram | director officer | Sale | 100,000 | - | Sep 25, 2026 |
| GRIMALDI CLAUDIA | director officer | Sale | 150,000 | - | Sep 25, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →IGC Growth Story
Revenue YoY
-5.5%
3yr Revenue CAGR
47.4%
EPS Growth YoY
59.09%
FCF Growth YoY
27.5%
Revenue Trend
STRONG
Dark Pool Trades for IGC
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for IGC, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 19:05:31 | $0.18 | 1,000 | $$177 | BUY |
| 18:58:32 | $0.18 | 7,400 | $$1K | BUY |
| 18:58:32 | $0.18 | 7,500 | $$1K | BUY |
| 18:06:57 | $0.18 | 2,563 | $$451 | SELL |
| 18:06:57 | $0.18 | 29,999 | $$5K | SELL |
5 dark pool trades shown · $$9K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for IGC Pharma, Inc. (IGC) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →IGC — frequently asked questions
What is IGC stock price today?
IGC Pharma, Inc. (IGC) is at $0.18, down 3.31% (-$0.01) at the Nov 13, 2026 close.
Why is IGC stock moving today?
Latest IGC news — Nov 6, 2026: IGC Pharma wins Canada patent covering IGC-AD1 for Alzheimer's-related agitation · Nov 5, 2026: IGC Pharma receives Canadian patent for IGC-AD1 Alzheimer's agitation therapy
What do analysts rate IGC?
Analyst ratings for IGC: 0 Buy, 3 Hold, 0 Sell — consensus Hold.
Did IGC beat earnings?
IGC last reported on Aug 17, 2026: EPS -$0.03 vs -$0.02 expected — a miss of 50.0%.
Does IGC pay a dividend?
IGC does not currently pay a dividend.
What are IGC support and resistance levels?
Support: $0.08. Resistance: $0.23, $0.27, $0.29.
What are insiders doing with IGC?
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
What is the latest news on IGC?
Nov 6, 2026: IGC Pharma wins Canada patent covering IGC-AD1 for Alzheimer's-related agitation · Nov 5, 2026: IGC Pharma receives Canadian patent for IGC-AD1 Alzheimer's agitation therapy